Vaxcyte, Inc.

NASDAQ:PCVX

Biotechnology

Healthcare
$58.52 +3.83%

+$1.94 today

Market cap
$9.26B
Beta
1.24
P/E (TTM)
-7.8
EPS (TTM)
-$6.78
52W Low $29.08High $65.00

Volume 1.13M

Average 1.44M

PCVX Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Vaxcyte, Inc.NASDAQ: PCVX

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows in line with its trailing trend

Q2 FY2026 weighted avg shares of 144.49M shares rose 6.2% year over year, behind the +7.3% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 3.6% from the prior quarter. Over 3 fiscal years it compounded at +28.0% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +6.2% toward the trailing-twelve-month pace of +7.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
144.49M+3.6% QoQ
Last fiscal yearDec 2025
136.09M+11.6% YoY
LTMJun 2026
139.07M+7.3% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.2%——
1 year+11.6%——
3-year CAGR+28.0%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
136.09M USD
Year-over-year change
+11.6%
4-year CAGR
+27.2%

Weighted Avg Shares vs competitors

How PCVX compares with its peers on the latest reported figures

  • PCVX's LTM Jun 2026 weighted avg shares of 139.07M shares is the 7th highest of the 9 companies compared; the peer median is 279.2M shares.
  • Its year-over-year change of +7.3% is the 3rd highest of 9, against a peer median of +2.7%.
  • Over three fiscal years its annual growth of +28.0% compares with a peer median of +1.3%.
PCVX Competitors Peer median
Weighted Avg Shares for PCVX and competitors
Company Period LTM YoY 3-year CAGR
PFEPfizer Inc.LTM Jun 20265.69B +0.3%+0.4%
GSKGSK plcLTM Jun 20262.01B -1.4%+0.2%
IBRXImmunityBio, Inc.LTM Sep 20261.03B +20.6%+32.0%
MRNAModerna, Inc.LTM Sep 2026396M +2.3%-0.4%
NVAXNovavax, Inc.LTM Mar 2026162.41M +3.2%+27.5%
VIRVir Biotechnology, Inc.LTM Mar 2026140.99M +3.1%+1.5%
PCVXVaxcyte, Inc.LTM Jun 2026139.07M +7.3%+28.0%
VALNValneva SELTM Mar 202683.89M +18.5%+13.4%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202627.53M +1.8%+1.2%
Peer median (excluding PCVX) 279.2M+2.7%+1.3%

Competitors are the stored peer set for PCVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development78.41M169.45M332.34M476.64M794.31M
Selling, General & Admin25.26M39.81M60.7M92.9M129.37M
Operating Expenses103.67M232.26M468.04M569.55M923.68M
Depreciation & Amortization3.46M9.45M10.17M15.85M24.86M
EBITDA(96.61M)(214.03M)(392.1M)(448.08M)(741.77M)
EBITDA Margin—————
Operating Income(103.67M)(232.26M)(468.04M)(569.55M)(923.68M)
Operating Margin—————
Interest Income344K8.36M62.91M109.99M119.72M
Interest Expense7K2K000
Other Income / Expenses3.59M8.77M65.78M105.62M157.05M
Income Before Tax(100.08M)(223.49M)(402.27M)(463.93M)(766.63M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(100.08M)(223.49M)(402.27M)(463.93M)(766.63M)
Net Margin—————
EPS (Basic)(1.93)(3.44)(4.14)(3.80)(5.63)
EPS (Diluted)(1.93)(3.44)(4.14)(3.80)(5.63)
Weighted Avg Shares51.92M64.88M97.16M122M136.09M
Weighted Avg Shares (Diluted)51.92M64.88M97.16M122M136.09M

Vaxcyte, Inc.

NASDAQ:PCVX

Intrinsic Alpha fair value

Locked

Current Price

$58.52

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.